Houot, Roch

KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma

Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 1,862

T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells

Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood

Immune cells in cancerLymphoma Diagnosis and Treatment

Cited by 168

Targeting CD137 enhances the efficacy of cetuximab

Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation

Immune Cell Function and InteractionMonoclonal and Polyclonal Antibodies Research

Cited by 160

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy

de Charette, M., & Houot, R. (2018) · Haematologica

Lymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 129

Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.

Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 41

CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies

Houot, R., & Kohrt, H. (2014) · OncoImmunology

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 15